Skip to Main Content

Paper Details

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Clin Cancer Res
44
2021
Author NameAffiliation
Dijana DjureinovicYale University School of Medicine
Marcus BosenbergYale University School of Medicine
Marcus BosenbergYale University School of Medicine
Marcus BosenbergYale University School of Medicine
Michael E HurwitzYale University School of Medicine
Harriet M KlugerYale University School of Medicine
Harriet M KlugerYale University School of Medicine
  • 1 - 7

Datasets

Release 1.2